Cargando…
Niclosamide: Beyond an antihelminthic drug
Niclosamide is an oral antihelminthic drug used to treat parasitic infections in millions of people worldwide. However recent studies have indicated that niclosamide may have broad clinical applications for the treatment of diseases other than those caused by parasites. These diseases and symptoms m...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628105/ https://www.ncbi.nlm.nih.gov/pubmed/28389414 http://dx.doi.org/10.1016/j.cellsig.2017.04.001 |
_version_ | 1783268822359212032 |
---|---|
author | Chen, Wei Mook, Robert A. Premont, Richard T. Wang, Jiangbo |
author_facet | Chen, Wei Mook, Robert A. Premont, Richard T. Wang, Jiangbo |
author_sort | Chen, Wei |
collection | PubMed |
description | Niclosamide is an oral antihelminthic drug used to treat parasitic infections in millions of people worldwide. However recent studies have indicated that niclosamide may have broad clinical applications for the treatment of diseases other than those caused by parasites. These diseases and symptoms may include cancer, bacterial and viral infection, metabolic diseases such as Type II diabetes, NASH and NAFLD, artery constriction, endometriosis, neuropathic pain, rheumatoid arthritis, sclerodermatous graft-versus-host disease, and systemic sclerosis. Among the underlying mechanisms associated with the drug actions of niclosamide are uncoupling of oxidative phosphorylation, and modulation of Wnt/β-catenin, mTORC1, STAT3, NF-κB and Notch signaling pathways. Here we provide a brief overview of the biological activities of niclosamide, its potential clinical applications, and its challenges for use as a new therapy for systemic diseases. |
format | Online Article Text |
id | pubmed-5628105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-56281052019-01-01 Niclosamide: Beyond an antihelminthic drug Chen, Wei Mook, Robert A. Premont, Richard T. Wang, Jiangbo Cell Signal Article Niclosamide is an oral antihelminthic drug used to treat parasitic infections in millions of people worldwide. However recent studies have indicated that niclosamide may have broad clinical applications for the treatment of diseases other than those caused by parasites. These diseases and symptoms may include cancer, bacterial and viral infection, metabolic diseases such as Type II diabetes, NASH and NAFLD, artery constriction, endometriosis, neuropathic pain, rheumatoid arthritis, sclerodermatous graft-versus-host disease, and systemic sclerosis. Among the underlying mechanisms associated with the drug actions of niclosamide are uncoupling of oxidative phosphorylation, and modulation of Wnt/β-catenin, mTORC1, STAT3, NF-κB and Notch signaling pathways. Here we provide a brief overview of the biological activities of niclosamide, its potential clinical applications, and its challenges for use as a new therapy for systemic diseases. Elsevier Inc. 2018-01 2017-04-04 /pmc/articles/PMC5628105/ /pubmed/28389414 http://dx.doi.org/10.1016/j.cellsig.2017.04.001 Text en © 2017 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Chen, Wei Mook, Robert A. Premont, Richard T. Wang, Jiangbo Niclosamide: Beyond an antihelminthic drug |
title | Niclosamide: Beyond an antihelminthic drug |
title_full | Niclosamide: Beyond an antihelminthic drug |
title_fullStr | Niclosamide: Beyond an antihelminthic drug |
title_full_unstemmed | Niclosamide: Beyond an antihelminthic drug |
title_short | Niclosamide: Beyond an antihelminthic drug |
title_sort | niclosamide: beyond an antihelminthic drug |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628105/ https://www.ncbi.nlm.nih.gov/pubmed/28389414 http://dx.doi.org/10.1016/j.cellsig.2017.04.001 |
work_keys_str_mv | AT chenwei niclosamidebeyondanantihelminthicdrug AT mookroberta niclosamidebeyondanantihelminthicdrug AT premontrichardt niclosamidebeyondanantihelminthicdrug AT wangjiangbo niclosamidebeyondanantihelminthicdrug |